Novartis ends open-label extension study of pelacarsen after Lp(a)HORIZON missNov 10Trial updateNovartispelacarsen
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Novartis clinicaltrials.gov records update across scleroderma, urticaria and SMA studiesOct 16Weekly roundup, 7 itemsianalumabNovartis
Novartis registers new Phase 2 NIO752 tauopathy trial; Egaten results, six studies updateOct 9Weekly roundup, 8 itemsinclisiraniptacopanUpdated
Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 studySep 4Clinical readoutIonis PharmaceuticalsNovartis
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib